• Meldonium 5ml 10 vials

Expiration date: 08/2023

Release form, composition and packaging:

Solution for injection 1 ml

Meldonium 100 mg

Capsules - cardboard boxes.

Pharmacological action : 

Tool, improves metabolism, analogue gamma-butirobetaina. Inhibits gamma-butyrobetaine, inhibits the synthesis of carnitine and transport of long chain fatty acids through membranes of cells, prevents accumulation in cells activated forms of unoxidized fatty acids - derivatives of acylcarnitine and acylcoenzyme A.

In conditions of ischemia it restores the equilibrium processes of oxygen delivery and consumption in cells, prevents violation transport ATP; simultaneously activates glycolysis, which occurs without any additional consumption of oxygen. As a result of lower concentrations of carnitine is synthesized hard gamma-butyrobetaine, vasodilating properties. Mechanism of action defines the variety of its pharmacological effects: improving health, reducing symptoms of mental and physical stress, activation of tissue and humoral immunity, cardioprotective effect.

In the case of acute ischemic myocardial damage slows the formation of necrotic zone, shortens the rehabilitation period. In heart failure increases myocardial contractility, increases exercise tolerance, reduces the frequency of angina attacks. In acute and chronic ischemic cerebrovascular disorders improves blood circulation in the ischemic focus, promotes redistribution of blood in favor of ischemic area. Effective at vascular and degenerative pathology of the ocular fundus. Has a tonic effect on the Central nervous system, eliminates functional disturbances of the nervous system in patients with chronic alcoholism the syndrome of abstinence.

Pharmacokinetics: 

After intake of rapidly absorbed from the gastrointestinal tract. Bioavailability of approximately 78%. Cmax in plasma achieved through 1-2 h after administration. Biotransformiroetsa in the body with the formation of two major metabolites, which are excreted by the kidneys. T1/2 is 3-6 h, depending on dose.

Indications : 

For oral administration or in/in the introduction: in the complex therapy CHD (angina, myocardial infarction), chronic heart failure, dishormonal cardiomyopathy; in the complex therapy of acute and chronic violations of cerebral circulation (stroke and cerebrovascular insufficiency); reduced working capacity, physical stress (including athletes), the postoperative period to speed rehabilitation; abstinence syndrome in chronic alcoholism (in combination with specific alcoholism therapy).

For parabulbarno introduction: acute violation of blood circulation in the retina, hemophthalmus and bleeding in the retina of different etiology, thrombosis Central retinal vein and its branches, retinopathy of different etiology (including diabetic and hypertensive) - only for parabulbarno injection.

Dosing regimen: 

In/in, parabulbarno.

Because of the possible development of exciting effect it is recommended to use in the first half of the day.

Cardiovascular disease

Unstable angina and myocardial infarction — in/jet, 0, 5-1 g 1 time per day. In the complex therapy, in/in (5-10 ml of solution for injection 100 mg/ml), applying the entire dose at once or divided into 2 times. The course of treatment — 4-6 weeks.

Cardialgia on background dyshormonal myocardial dystrophy — in bolus at 0, 5-1 1 g once a day, treatment course — 10-14 days.

Violation of cerebral circulation. 

The acute phase of cerebrovascular disease — 500 mg 1 time per day, in/in, in 10 days. If necessary, possibly re courses.

Ophthalmology

Hemophthalmus and bleeding in the retina of different etiology, thrombosis Central retinal vein and its branches, retinopathy of different etiology (diabetic, hypertension) — parabulbarno 0, 5 ml 100 mg/ml for 10 days.

Chronic alcoholism

In/in, 500 mg 2 times a day. The course of treatment — 7-10 days.

Precautions when applying. 

Patients with chronic diseases of the liver and kidney, caution should be exercised with prolonged use of the drug. There is no sufficient data about the use of Meldonium in children.

Side effects: 

Of the cardiovascular system: rarely- tachycardia, change AD.

CNS: rarely - agitation.

From the digestive system: rare - dyspeptic symptoms.

Allergic reactions: rarely - itching, redness, rash, swelling.

Contraindications: 

Increased intracranial pressure (including, in cases of impaired venous drainage, intracranial tumors), pregnancy, lactation (breastfeeding), childhood and adolescence to 18 years, increased sensitivity to melidoniou.

Application of pregnancy and breast-feeding: 

During pregnancy and lactation (breastfeeding) the drug is contraindicated.

Application for violations of liver function: 

To apply caution in diseases of the liver, especially for a long time.

Application for violations of renal function: 

To apply caution in diseases of the kidneys, especially for a long time.

Use in children: 

In children and adolescents under 18 years the efficacy and safety of Meldonium is not installed.

Meldonium in the form of capsules is contraindicated in children and adolescents under 18 years of age; in the form of syrup - in children under 12 years.

Special instructions: 

To apply caution in diseases of the liver and/or kidneys, especially for a long time.

Many years of experience in the treatment of acute myocardial infarction and unstable angina in cardiology departments shows that Meldonium is not the first number in acute coronary syndrome.

Drug interactions: 

In a joint application Meldonium increases the effects of antianginal of funds, some antihypertensive drugs, cardiac glycosides.

While the use of Meldonium nitroglycerin, nifedipine, alpha-blockers, antihypertensive agents and peripheral vasodilators may develop a moderate tachycardia, arterial hypotension (in these combinations requires caution).

Storage conditions: 

In protected from light place, at temperature not above 25 °C.

Keep out of reach of children.

Meldonium
5ml
10
vials

  • $10.00